Asset profile
Mevidalen
Small molecule
Evidence outlook · lead readout
NCT06538116 · Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06538116: The trial randomized 304 participants to two mevidalen dose groups or placebo and used double blinding of participants and investigators. Its primary clinical cognitive-and-functional endpoint was specified, but results and statistical comparisons are not yet available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.